FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2966634303> ?p ?o ?g. }

• W2966634303 endingPage "973" @default.
• W2966634303 startingPage "973" @default.
• W2966634303 abstract "Abstract Clinical trials in sickle cell disease (SCD) continue to have challenges achieving clinical endpoints. Most SCD clinical trials have focused on painful vaso-occlusive crisis (VOC) episodes because they are prevalent, debilitating and often lead to medical contact. However with VOC as a clinical endpoint: there are no objective, quantifiable biomarkers of pain; pain may not be specific to VOC; the threshold for medical contact varies between patients; VOCs occurring at home without medical contact are not captured; other components of VOC (e.g., fatigue, functioning) are poorly assessed. We therefore undertook the present non-interventional, longitudinal study to test novel tools for the identification of VOCs occurring in SCD patients with varying degrees of medical contact. During 6 months of evaluation, longitudinal measures of pain, fatigue, function, activity (by actigraphy), clinical laboratory and biomarker samples from SCD patients (+/- hydroxyurea therapy) in steady state to VOC were studied. A novel electronic patient-reported outcome tool (ePRO) enabled patients to self-report daily pain, fatigue, function, and medication use. It was also used to report VOC in real time, triggering an alert to a mobile phlebotomy team. Blood collections were taken within 24 and 48 hours of self-reported VOC onset (either at home, emergency department [ED], or hospital). Follow-up blood samples were collected 2 days after resolution of the VOC. Baseline blood samples were drawn at home every 3 weeks during stable, non-VOC periods. Biomarker assays included leukocyte-platelet aggregates and circulating microparticles measured by flow cytometry, cell adhesion in microfluidic flow-based assays to immobilized vascular cell adhesion molecule or P-selectin, and a panel of soluble adhesion molecules, cytokines, inflammatory mediators and coagulation factors. Patients wore a Phillips Actiwatch Spectrum™ actigraphy device to track sleep and activity. Patient-reported outcomes, activity, and biomarkers on non-VOC days were compared to those on VOC days using a mixed model approach and results are reported as means with 95% confidence intervals (95%CI). In this study 27 of 35 patients experienced a total of 286 days with VOC &gt;4 hr (VOC days), of which only 58 days (20%) resulted in healthcare utilization such as contacting provider, visiting ED and/or hospitalization. VOC days had significantly higher pain scores (scale: 0-10) with worst pain score increased by 4.5 (95% CI 4.3-4.7) compared to non-VOC days. VOCs requiring medical contact had significantly higher worst pain scores compared to at-home VOCs. Similar changes observed with reported least, average and pain right now. VOC days had significantly higher fatigue scores by 2.3 (95% CI 2.1-2.5) points (scale: 0-10). However, fatigue scores during at-home VOCs were not different from VOCs requiring medical contact. VOC days were associated with significantly decreased functional scores (physical, social, self-care and role activity), with significantly greater decreases during VOCs requiring medical contact compared to at-home VOCs. Different activity profiles were identified for non-VOC, at-home VOC and medical contact VOC days by actigraphy monitoring. At-home VOC days exhibited increased (34%, 95% CI 9%-64%) daytime resting compared to non-VOC days. Medical contact VOCs had decreased average and peak activity, and increased daytime resting compared to non-VOC days. A sleep fragmentation index trended up for both at-home (16%) and medical contact VOC days (18%). Significant changes during VOC days were observed in a subset of clinical laboratory and biomarker measures. Examples include: C-reactive protein (54% increase) and nucleated RBC (34% increase) in the clinical laboratory panel; monocyte-platelet aggregates (25% increase) and neutrophil-platelet aggregates (35% increase) in the biomarker panel. This innovative at-home study design demonstrates the feasibility of monitoring out of hospital pain and use of patient-reported VOC day as a potential endpoint for clinical trials. Electronic patient-reported outcomes, actigraphy and clinical laboratory and biomarkers may enable improved identification and assessment of at-home VOCs for further clinical studies. Disclosures Callaghan: CSL Behring: Membership on an entity's Board of Directors or advisory committees; Grifols: Membership on an entity's Board of Directors or advisory committees; Biogen: Membership on an entity's Board of Directors or advisory committees; Global Blood Therapeutics: Other: Site PI; Baxalta: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche/Genentech: Membership on an entity's Board of Directors or advisory committees, Other: Site PI, Speakers Bureau; Octapharma: Membership on an entity's Board of Directors or advisory committees; Alnylam Pharmaceuticals, Inc: Other: Owns stock, stock options, or bonds ; Shire: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Bayer HealthCare; Pfizer Inc.; Roche; Shire: Consultancy; Sancillio: Other: Site PI; Bayer: Membership on an entity's Board of Directors or advisory committees; Pfizer Inc.: Membership on an entity's Board of Directors or advisory committees, Other: Site PI, Research Funding; Roche; Shire: Speakers Bureau; Novo Nordisk: Speakers Bureau. Pittman: Pfizer: Employment. Beidler: Pfizer: Employment. Rybin: Pfizer: Employment. Liu: Functional Fluidics: Employment. Pleil: Pfizer: Employment. Barsdorf: Pfizer: Employment. David: Pfizer: Employment. Simmons: Pfizer: Employment. Frelinger: Baxalta: Research Funding; Ionis: Research Funding; Sysmex: Research Funding; Pfizer: Research Funding; Ironwood: Research Funding; GLSynthesis: Research Funding. Michelson: Eisai: Research Funding; Ionis: Research Funding; Ironwood: Research Funding; Pfizer: Research Funding; Sysmex: Research Funding; GLSynthesis: Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees; Instrumentation Laboratory: Consultancy; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; Elsevier: Patents & Royalties; Baxalta: Research Funding. Clarke: Pfizer: Employment. Charnigo: Pfizer: Employment." @default.
• W2966634303 created "2019-08-13" @default.
• W2966634303 creator A5000917771 @default.
• W2966634303 creator A5009915557 @default.
• W2966634303 creator A5013218915 @default.
• W2966634303 creator A5020286464 @default.
• W2966634303 creator A5023842540 @default.
• W2966634303 creator A5024712381 @default.
• W2966634303 creator A5025681609 @default.
• W2966634303 creator A5033479502 @default.
• W2966634303 creator A5033610772 @default.
• W2966634303 creator A5049630475 @default.
• W2966634303 creator A5054448346 @default.
• W2966634303 creator A5065780198 @default.
• W2966634303 creator A5067192657 @default.
• W2966634303 creator A5069661827 @default.
• W2966634303 creator A5070577705 @default.
• W2966634303 creator A5079756072 @default.
• W2966634303 creator A5079851077 @default.
• W2966634303 creator A5087930282 @default.
• W2966634303 date "2017-12-07" @default.
• W2966634303 modified "2023-09-30" @default.
• W2966634303 title "Elipsis: A Longitudinal Study of Electronic Patient-Reported Outcomes, Actigraphy and Biomarkers to Identify and Assess at-Home Vaso-Occlusive Crises in Adults and Adolescents with Sickle Cell Disease" @default.
• W2966634303 doi "https://doi.org/10.1182/blood.v130.suppl_1.973.973" @default.
• W2966634303 hasPublicationYear "2017" @default.
• W2966634303 type Work @default.
• W2966634303 sameAs 2966634303 @default.
• W2966634303 citedByCount "3" @default.
• W2966634303 countsByYear W29666343032018 @default.
• W2966634303 countsByYear W29666343032019 @default.
• W2966634303 crossrefType "journal-article" @default.
• W2966634303 hasAuthorship W2966634303A5000917771 @default.
• W2966634303 hasAuthorship W2966634303A5009915557 @default.
• W2966634303 hasAuthorship W2966634303A5013218915 @default.
• W2966634303 hasAuthorship W2966634303A5020286464 @default.
• W2966634303 hasAuthorship W2966634303A5023842540 @default.
• W2966634303 hasAuthorship W2966634303A5024712381 @default.
• W2966634303 hasAuthorship W2966634303A5025681609 @default.
• W2966634303 hasAuthorship W2966634303A5033479502 @default.
• W2966634303 hasAuthorship W2966634303A5033610772 @default.
• W2966634303 hasAuthorship W2966634303A5049630475 @default.
• W2966634303 hasAuthorship W2966634303A5054448346 @default.
• W2966634303 hasAuthorship W2966634303A5065780198 @default.
• W2966634303 hasAuthorship W2966634303A5067192657 @default.
• W2966634303 hasAuthorship W2966634303A5069661827 @default.
• W2966634303 hasAuthorship W2966634303A5070577705 @default.
• W2966634303 hasAuthorship W2966634303A5079756072 @default.
• W2966634303 hasAuthorship W2966634303A5079851077 @default.
• W2966634303 hasAuthorship W2966634303A5087930282 @default.
• W2966634303 hasConcept C118552586 @default.
• W2966634303 hasConcept C121446783 @default.
• W2966634303 hasConcept C126322002 @default.
• W2966634303 hasConcept C185592680 @default.
• W2966634303 hasConcept C203092338 @default.
• W2966634303 hasConcept C2777357209 @default.
• W2966634303 hasConcept C2778620579 @default.
• W2966634303 hasConcept C2778996325 @default.
• W2966634303 hasConcept C2779134260 @default.
• W2966634303 hasConcept C2780441568 @default.
• W2966634303 hasConcept C2780724011 @default.
• W2966634303 hasConcept C2781197716 @default.
• W2966634303 hasConcept C535046627 @default.
• W2966634303 hasConcept C55493867 @default.
• W2966634303 hasConcept C71924100 @default.
• W2966634303 hasConceptScore W2966634303C118552586 @default.
• W2966634303 hasConceptScore W2966634303C121446783 @default.
• W2966634303 hasConceptScore W2966634303C126322002 @default.
• W2966634303 hasConceptScore W2966634303C185592680 @default.
• W2966634303 hasConceptScore W2966634303C203092338 @default.
• W2966634303 hasConceptScore W2966634303C2777357209 @default.
• W2966634303 hasConceptScore W2966634303C2778620579 @default.
• W2966634303 hasConceptScore W2966634303C2778996325 @default.
• W2966634303 hasConceptScore W2966634303C2779134260 @default.
• W2966634303 hasConceptScore W2966634303C2780441568 @default.
• W2966634303 hasConceptScore W2966634303C2780724011 @default.
• W2966634303 hasConceptScore W2966634303C2781197716 @default.
• W2966634303 hasConceptScore W2966634303C535046627 @default.
• W2966634303 hasConceptScore W2966634303C55493867 @default.
• W2966634303 hasConceptScore W2966634303C71924100 @default.
• W2966634303 hasIssue "Suppl_1" @default.
• W2966634303 hasLocation W29666343031 @default.
• W2966634303 hasOpenAccess W2966634303 @default.
• W2966634303 hasPrimaryLocation W29666343031 @default.
• W2966634303 hasRelatedWork W167982285 @default.
• W2966634303 hasRelatedWork W2046855179 @default.
• W2966634303 hasRelatedWork W2048128183 @default.
• W2966634303 hasRelatedWork W2078446165 @default.
• W2966634303 hasRelatedWork W2155159475 @default.
• W2966634303 hasRelatedWork W2160475077 @default.
• W2966634303 hasRelatedWork W2790789677 @default.
• W2966634303 hasRelatedWork W2966634303 @default.
• W2966634303 hasRelatedWork W2975260264 @default.
• W2966634303 hasRelatedWork W4210544780 @default.
• W2966634303 hasVolume "130" @default.
• W2966634303 isParatext "false" @default.
• W2966634303 isRetracted "false" @default.
• W2966634303 magId "2966634303" @default.
• W2966634303 workType "article" @default.